Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of AtriCure, Inc. (NASDAQ:ATRC)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in AtriCure stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

AtriCure Stock Performance

NASDAQ:ATRC opened at $56.87 on Wednesday. The company has a market capitalization of $2.89 billion, a price-to-earnings ratio of 270.82 and a beta of 1.24. The business has a 50 day moving average of $51.69 and a 200 day moving average of $37.70. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $61.70.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ATRC. BlackRock Inc. bought a new position in shares of AtriCure in the second quarter worth about $125,198,000. Wellington Management Group LLP lifted its holdings in AtriCure by 3.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock worth $97,807,000 after purchasing an additional 113,048 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in AtriCure by 8.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares during the period. Bank of America Corp DE bought a new position in AtriCure in the 2nd quarter worth approximately $24,465,000. Finally, Grandeur Peak Global Advisors LLC bought a new position in AtriCure in the 2nd quarter worth approximately $16,435,000. Institutional investors own 99.11% of the company’s stock.

Insider Buying and Selling at AtriCure

In other news, Director Regina Groves sold 5,313 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the transaction, the director owned 34,546 shares of the company’s stock, valued at approximately $1,873,084.12. The trade was a 13.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Salvatore Privitera sold 4,519 shares of the company’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00. Following the transaction, the insider owned 142,745 shares of the company’s stock, valued at approximately $8,564,700. This represents a 3.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 74,868 shares of company stock worth $3,317,897. Insiders own 4.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on ATRC shares. Piper Sandler upped their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. UBS Group dropped their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. Finally, Zacks Research cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.10.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.